Page Title
We live product development – transforming ground-breaking ideas into life-saving medication.


VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients

Vakzine Projekt Management GmbH (VPM) announced today that it has supported Memo Therapeutics AG (MTx) during the process for receiving fast track designation from the U.S. Food and Drug Administration (FDA) for the novel human monoclonal antibody, AntiBKV, developed by MTx for the treatment of BK viremia in kidney transplant recipients. READ MORE

VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana

Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the novel R21/Matrix-MTM Malaria Vaccine by the Ghana Food and Drugs Authority (FDA) for use in children as young as 5 months old up to 36 months old, in Ghana. This approval is an exciting milestone and was achieved by the joint global efforts of VPM, Serum Institute of India (SII), Oxford University, and DEK Vaccines Ltd (DEK). This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa READ MORE

VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

We are pleased to announce the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met. Click here for more information.

Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases

The course of respiratory infectious disease pandemics, will strongly depend on how quickly medications or specific vaccines against the pathogens are available. Researchers wanted to investigate in a phase III trial whether the vaccine candidate VPM1002 is also protective against an infection with the novel SARS-CoV-2. The large-scale study has been carried out at several hospitals in Germany and included older people that are susceptible to severe course of the disease. Read about the results here!